Questions Surround FDA's Orphan Drug Exclusivity Approach
On Jan. 24, the U.S. Food and Drug Administration issued a notice to clarify orphan drug exclusivity following the U.S. Court of Appeals for the Eleventh Circuit's 2021 ruling in Catalyst...To view the full article, register now.
Already a subscriber? Click here to view full article